Related Experiment Video

Updated: May 25, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology

Xue Xue1, Xing-Jie Liang

  • 1National Center for Nanoscience and Technology of China, Beijing 100190, People's Republic of China.

Chinese Journal of Cancer
|January 13, 2012
PubMed

Insights

Multidrug resistance (MDR) in cancer treatment is a major challenge. Nanoparticle-based theranostic strategies show promise in overcoming drug efflux mechanisms and improving therapeutic outcomes.

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) significantly reduces chemotherapy efficacy and leads to tumor recurrence.
  • P-glycoprotein (P-gp) and other efflux transporters are key mechanisms driving MDR by expelling anticancer drugs from cells.
  • Overcoming MDR is crucial for improving patient survival rates in cancer treatment.

Purpose of the Study:

  • To review the mechanisms of drug efflux-mediated multidrug resistance in cancer.
  • To explore the application of nanoparticle-based theranostic platforms to overcome chemoresistance.
  • To discuss how these innovative strategies can improve therapeutic outcomes in cancer patients.

Main Methods:

  • Literature review of studies on multidrug resistance mechanisms.
  • Analysis of research on nanoparticle-based drug delivery systems for cancer therapy.
  • Discussion of theranostic approaches combining therapeutic and diagnostic capabilities.

Main Results:

  • Drug efflux transporters like P-gp are critical in mediating resistance to chemotherapy.
  • Nanoparticle platforms offer potential strategies to bypass or inhibit these efflux mechanisms.
  • Theranostic nanoparticles can enhance drug delivery, monitor treatment response, and overcome MDR.

Conclusions:

  • Nanoparticle-based theranostics represent a promising avenue for overcoming multidrug resistance in cancer.
  • Targeting drug efflux mechanisms with advanced delivery systems can improve chemotherapy effectiveness.
  • Further research into nanoparticle applications is essential for advancing cancer treatment strategies.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...